SCHEMBL2669728

SCHEMBL2669728

CCCCOCCCOc1ccc(CC(C(=O)O)c2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.50
▸ HRH3 Q9Y5N1 3/20 0.48
▸ POLB P06746 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ PPARA Q07869 3/20 0.45
▸ PPARG P37231 2/20 0.45
▸ PTGES O14684 1/20 0.45
▸ ALOX5 P09917 1/20 0.45
▸ PPARD Q03181 2/20 0.45
▸ MMP9 P14780 1/20 0.45
▸ MMP8 P22894 1/20 0.45
▸ MMP13 P45452 1/20 0.45
▸ NR4A2 P43354 1/20 0.43
▸ RXRA P19793 1/20 0.43
▸ RXRB P28702 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MITF O75030 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2669618 0.97 LMNA (0.49) LMNAHRH3POLBTDP1L3MBTL1
SCHEMBL11999238 0.95 LMNA (0.54) LMNAPOLBTDP1L3MBTL1PPARA
SCHEMBL2669629 0.91 LMNA (0.50) LMNAPOLBTDP1L3MBTL1NR4A2
SCHEMBL2669746 0.89 ESR1 (0.50) LMNAHRH3POLBKDM4EMITF
SCHEMBL2657103 0.88 GAA (0.48) LMNAHRH3POLBTDP1L3MBTL1
SCHEMBL2669616 0.86 ESR1 (0.49) LMNAHRH3POLBPPARAPPARG
SCHEMBL2669617 0.84 ESR1 (0.54) LMNAPOLBMMP9MMP8MMP13
SCHEMBL2662588 0.82 PPARG (0.48) LMNAPOLBTDP1L3MBTL1PPARA
SCHEMBL11999235 0.79 ESR1 (0.54) LMNAL3MBTL1PPARAPPARGPPARD
SCHEMBL2656926 0.79 KMT2A (0.53) LMNAHRH3POLBPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 — — US disclosed
US-9701626-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2017-07-11 — — US disclosed
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2016-01-14 — — US disclosed
US-9169201-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2015-10-27 — — US disclosed
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 — — EP disclosed
EP-2129654-B1 ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2014-05-28 — — EP disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 — — US disclosed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 LMNA 2993/4885HRH3 1074/4885POLB 4502/4885
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 LMNA 2993/4885HRH3 1074/4885POLB 4502/4885
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor GLP1R, GCGR, GPR119 LMNA 2993/4885HRH3 1074/4885POLB 4502/4885
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 LMNA 2993/4885HRH3 1074/4885POLB 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback